测量非小细胞肺癌 (NSCLC) 患者的动态对比增强磁共振成像 (DCE-MRI) 生物标志物重复性。为了利用这些统计数据来确定哪些个体目标病灶表现出早期生物反应。2015 年 9 月至 2017 年 4 月期间进行了一项单中心前瞻性 DCE-MRI 研究。在标准护理放疗之前对 NSCLC 患者进行了扫描，以评估生物标志物的可重复性治疗两周后评估生物反应。在每个时间点测量体积转移常数（Ktrans）、血管外细胞外空间体积分数（ve）和血浆体积分数（vp）以及肿瘤体积。使用受试者内变异系数（wCV）和重复性系数（RC）评估重复性。使用混合效应模型估计队列治疗对生物标志物的影响。 RC 一致性限制揭示了哪些个体目标病变的变化超出了生物标志物每日变化的预期。14 名患者（平均年龄，67 岁/- 12，8 名男性）有 22 个可评估病变（12 个原发肿瘤，8 个淋巴结转移，2 个远处转移） 。除了 vp 为 42.44% 外，所有生物标志物的 wCV（8/14 例患者）在 9.16% 至 17.02% 之间。 Ktrans 和 ve (p<0.001) 以及肿瘤体积 (p=0.002) 的队列水平变化显着。 Ktrans 和肿瘤体积一致显示显示生物反应的单个病变数量最多。相比之下，尽管队列水平发生了变化，但没有单个病变在 ve 中发生真正的变化。识别个体早期生物反应者为传统队列队列水平统计数据提供了额外的信息，有助于确定哪些参数最适合未来使用研究。动态对比增强磁共振成像生物标志物 Ktrans 和肿瘤体积是可重复的，可以检测队列和个体病变水平的早期治疗引起的变化，支持它们在放射治疗和靶向治疗的进一步评估中的使用。很少有文献研究报告定量成像生物标志物精度，通过测量重复性或再现性。肺癌肿瘤微环境的几种 DCE-MRI 生物标志物具有高度可重复性。重复性系数测量能够对治疗的早期生物反应进行特定病变的评估，从而改进传统评估。© 2024。作者。

To measure dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) biomarker repeatability in patients with non-small cell lung cancer (NSCLC). To use these statistics to identify which individual target lesions show early biological response.A single-centre, prospective DCE-MRI study was performed between September 2015 and April 2017. Patients with NSCLC were scanned before standard-of-care radiotherapy to evaluate biomarker repeatability and two weeks into therapy to evaluate biological response. Volume transfer constant (Ktrans), extravascular extracellular space volume fraction (ve) and plasma volume fraction (vp) were measured at each timepoint along with tumour volume. Repeatability was assessed using a within-subject coefficient of variation (wCV) and repeatability coefficient (RC). Cohort treatment effects on biomarkers were estimated using mixed-effects models. RC limits of agreement revealed which individual target lesions changed beyond that expected with biomarker daily variation.Fourteen patients (mean age, 67 years +/- 12, 8 men) had 22 evaluable lesions (12 primary tumours, 8 nodal metastases, 2 distant metastases). The wCV (in 8/14 patients) was between 9.16% to 17.02% for all biomarkers except for vp, which was 42.44%. Cohort-level changes were significant for Ktrans and ve (p < 0.001) and tumour volume (p = 0.002). Ktrans and tumour volume consistently showed the greatest number of individual lesions showing biological response. In distinction, no individual lesions had a real change in ve despite the cohort-level change.Identifying individual early biological responders provided additional information to that derived from conventional cohort cohort-level statistics, helping to prioritise which parameters would be best taken forward into future studies.Dynamic contrast-enhanced magnetic resonance imaging biomarkers Ktrans and tumour volume are repeatable and detect early treatment-induced changes at both cohort and individual lesion levels, supporting their use in further evaluation of radiotherapy and targeted therapeutics.Few literature studies report quantitative imaging biomarker precision, by measuring repeatability or reproducibility. Several DCE-MRI biomarkers of lung cancer tumour microenvironment were highly repeatable. Repeatability coefficient measurements enabled lesion-specific evaluation of early biological response to therapy, improving conventional assessment.© 2024. The Author(s).